Estimated Read Time:

1 minute

SABCS Snippets: Results from the Phase III HER2CLIMB-05 Trial

Julie Nangia, MD, talks with Erika Hamilton, MD, about the results of the HER2CLIMB-05 study, a Phase III trial that demonstrated that adding tucatinib to first-line maintenance therapy with trastuzumab and pertuzumab delayed disease progression in patients with HER2-positive metastatic breast cancer, potentially extending time off chemotherapy.

Share

Recent Posts